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Background: Clopidogrel is widely used for treatment of acute coronary syndrome but there is increasing evidence concerning its limited 
antiplatelet activity especially in Asian population. Prasugrel has been shown to have superior efficacy in platelet inhibition compared to clopidogrel 
and it has been translated to improved clinical outcomes but increased bleeding risk.
Methods: From December 2010, chinese patients admitted with acute coronary syndrome who are clopidogrel or prasugrel naïve were treated with 
either loading doses of clopidogrel 300mg or 600mg, or prasugrel 60mg at physicians’ discretion. Antiplatelet activities were evaluated by VerifyNow 
P2Y12 at 4-6 hours and 24 hours after loading.
Results: 56 patients were recruited into study. 17 patients received clopidogrel 300mg, 28 patients received clopidogrel 600mg and 11 patients 
received prasugrel 60mg. Mean platelet reactivity units (PRU) at 4-6 hours and 24 hours in clopidogrel 300mg group are 290+/-75 and 230+/-95 
respectively, in clopidrgrel 600mg group 295+/-94 and 267+/-106 respectively, in prasugel 60mg group 51+/-96 and 17+/-21 respectively. PRU in 
prasugrel group is significantly lower than that in clopidogrel 300mg and 600mg group (p<0.005) while there is no difference between clopidogrel 
300mg and 600mg group. The percentage of clopidogrel hyporesponsiveness (as defined by PRU>230) are 71% at 4-6 hours and 49% at 24 hours 
while percentage of prasugrel hyporesponiveness is 9% at 4-6 hours and 0% at 24 hours.
Conclusions: A loading dose of prasugrel 60mg in local chinese patients with acute coronary syndrome has significantly more potent and rapid 
antiplatelet effect than loading clopidogrel 300mg or 600mg. Further studies are necessary to delineate whether such dramatic difference will 
translate into superior clinical efficacy or increased bleeding risk of prasugrel in chinese patients presenting with acute coronary syndrome.
